Table 1.

In vitro combination study of NT157 with conventional and targeted drugs in OS cells.

Drug combination	MG-63		U-2OS
	CI ± SE	Effects	CI ± SE	Effects
NT157 + Everolimus	0.66 ± 0.2	Synergistic	0.47 ± 0.08	Synergistic
NT157 + NVP-BEZ235	0.59 ± 0.06	Synergistic	0.82 ± 0.02	Synergistic
NT157 + Doxorubicin	0.79 ± 0.06	Synergistic	1.55 ± 0.7	Additive
NT157 + CDDP	0.92 ± 0.08	Sub-additive	1.22 ± 0.05	Additive
NT157 + MTX	1.11 ± 0.05	Additive	>100	Additive